{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:39Z","timestamp":1792427739420,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00296-019-04268-x","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T06:42:25Z","timestamp":1552545745000},"page":"743-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-3905","authenticated-orcid":false,"given":"D\u00f6nd\u00fc","family":"\u00dcsk\u00fcdar Cansu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Demirta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan","family":"Andi\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4434-4580","authenticated-orcid":false,"given":"Hava","family":"\u00dcsk\u00fcdar Teke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0699","authenticated-orcid":false,"given":"Cengiz","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"4268_CR1","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77:1865\u20131879","journal-title":"Drugs"},{"key":"4268_CR2","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF (2011) Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 13:R141","journal-title":"Arthritis Res Ther"},{"key":"4268_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jbspin.2016.04.008","volume":"84","author":"N Martis","year":"2017","unstructured":"Martis N, Chirio D, Queyrel-Moranne V, Zenut MC, Rocher F, Fuzibet JG (2017) Tocilizumab-induced hypofibrinogenemia: a report of 7 cases. Jt Bone Spine 84:369\u2013370","journal-title":"Jt Bone Spine"},{"key":"4268_CR4","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jbspin.2017.02.012","volume":"84","author":"G Vitiello","year":"2017","unstructured":"Vitiello G, Orsi Battaglini C, Radice A, Carli G, Micheli S, Cammelli D (2017) Sustained tocilizumab-induced hypofibrinogenemia and thrombocytopenia. comment on: \u201cTocilizumab-induced hypofibrinogenemia: a report of 7 cases\u201d by Martis et al. Jt Bone Spine 84:649\u2013650","journal-title":"Jt Bone Spine"},{"key":"4268_CR5","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12185-012-1191-x","volume":"96","author":"M Matsuoka","year":"2012","unstructured":"Matsuoka M, Majima T, Onodera T, Ieko M, Souri M, Ichinose A, Kurita T, Kasahara Y, Inoue M, Takahashi D (2012) Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol 96:781\u2013785","journal-title":"Int J Hematol"},{"key":"4268_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/14397595.2018.1428041","volume":"28","author":"H Imamura","year":"2018","unstructured":"Imamura H, Momohara S, Yano K, Sakuma Y, Nakayama M, Tobimatsu H, Ikari K (2018) Tocilizumab treatment in patients with rheumatoid arthritis is associated with reduced fibrinogen levels and increased blood loss after total knee arthroplasty. Mod Rheumatol 28:976\u2013980","journal-title":"Mod Rheumatol"},{"key":"4268_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2016.02.026","volume":"140","author":"M Souri","year":"2016","unstructured":"Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A (2016) Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res 140:100\u2013105","journal-title":"Thromb Res"},{"key":"4268_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","volume":"36","author":"T Okano","year":"2016","unstructured":"Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Wakitani S, Koike T, Nakamura H (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36:349\u2013357","journal-title":"Rheumatol Int"},{"key":"4268_CR9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417","journal-title":"Rheumatol Int"},{"key":"4268_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239\u2013245","journal-title":"Clin Pharmacol Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04268-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:26:26Z","timestamp":1584059186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04268-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["4268"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04268-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"11 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from our patient included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}